Foa R, Meloni G, Guarini A, Vignetti M, Marchis D, Tosti S, Tos A G, Vischia F, Mandelli F, Gavosto F
Dipartimento di Scienze Biomediche e Oncologia Umana, University of Torino, Italy.
Leukemia. 1992;6 Suppl 3:115S-116S.
In this paper we review some of the preclinical findings which have led us to believe that immunotherapy with interleukin 2 (IL2)/lymphokine activated killer (LAK) cells may be a feasible approach in the management of acute myeloid leukemia. The main clinical and biological results so far obtained with IL2 treatment, and the currently ongoing protocols and strategies are discussed.
在本文中，我们回顾了一些临床前研究结果，这些结果使我们相信，白细胞介素2（IL2）/淋巴因子激活的杀伤细胞（LAK）免疫疗法可能是治疗急性髓系白血病的一种可行方法。本文还讨论了迄今为止用IL2治疗所获得的主要临床和生物学结果，以及目前正在进行的方案和策略。
